Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.68 |
| ▸ | CA1 | P00915 | 1/20 | 0.68 |
| ▸ | CA2 | P00918 | 1/20 | 0.68 |
| ▸ | CA4 | P22748 | 1/20 | 0.68 |
| ▸ | CA5A | P35218 | 1/20 | 0.68 |
| ▸ | CA7 | P43166 | 1/20 | 0.68 |
| ▸ | CA9 | Q16790 | 1/20 | 0.68 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.59 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.59 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.59 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.59 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.57 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.57 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1424430 | 0.98 | CA12 (0.70) | CA12CA1CA2CA4CA5A | |
| Hydrochloric Acid SCHEMBL28119647 | 0.97 | CA12 (0.68) | CA12CA1CA2CA4CA5A | |
| SCHEMBL27476966 | 0.86 | ALOX5 (0.61) | CA12CA1CA2CA4CA5A | |
| SCHEMBL2331902 | 0.84 | ALOX5 (0.63) | CA12CA1CA2CA4CA5A | |
| SCHEMBL7108878 | 0.84 | CA12 (0.74) | CA12CA1CA2CA4CA5A | |
| Benzylphenylether SCHEMBL4275393 | 0.83 | LMNA (0.64) | CA12CA1CA2CA4CA5A | |
| SCHEMBL6949461 | 0.83 | CA12 (0.69) | CA12CA1CA2CA7CA9 | |
| SCHEMBL9999620 | 0.82 | CA12 (0.51) | CA12CA1CA2CA4CA5A | |
| SCHEMBL10983895 | 0.82 | AR (0.57) | CA12CA1CA2CA4CA5A | |
| SCHEMBL28508086 | 0.82 | CA12 (0.72) | CA12CA1CA2CA4CA5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4087369-A | SURFACTANTS, BUILDERS, STORAGE STABILITY | THE PROCTER & GAMBLE COMPANY (US) | 1978-05-02 | — | — | US | claimed |
| EP-3774777-A2 | MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | Arvinas Operations, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| US-20100152255-A1 | Organic Compounds | DAMON ROBERT EDSON | 2010-06-17 | — | — | US | disclosed |
| US-7700637-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-04-20 | — | — | US | disclosed |
| CN-100482649-C | Organic compounds | NOVARTIS AG (CH) | 2009-04-29 | — | — | CN | disclosed |
| US-20070004704-A1 | Such as 6-Methyl-2-[4-(5-methyl-2-phenyl-oxazol-4-ylmethoxy)-benzenesulfonylamino]-benzoic acid which binds Peroxisome Proliferator-Activated Receptors; conditions in which impaired glucose tolerance, hyperglycemia and insulin resistance are implicated, such as type-1 and type-2 diabetes, and Syndrome X | NOVARTIS AG (CH) | 2007-01-04 | — | — | US | disclosed |
| CN-1852901-A | Organic compounds | NOVARTIS AG (CH) | 2006-10-25 | — | — | CN | disclosed |
| EP-1664002-A1 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005026134-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2005-03-24 | — | — | WO | disclosed |
| CN-1316995-A | Hydroxy 2-piperidinoate hydroxamic acid derivatives as MMP inhibitors | PFIZER PROD INC (US) | 2001-10-10 | — | — | CN | disclosed |
| US-5677112-A | USING AN ANTHRACENE COMPOUND | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 1997-10-14 | — | — | US | disclosed |
| US-5576359-A | ANTHRACENE DERIVATIVE, SOLVENT, COMPOUND CONTAINING GLYCIDYL GROUPS | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 1996-11-19 | — | — | US | disclosed |
| EP-0636941-B1 | Deep ultraviolet absorbent and its use in pattern formation | WAKO PURE CHEM IND LTD (JP) | 1996-03-20 | — | — | EP | disclosed |
| US-5444056-A | Hypotensive agnets, calcium channel blockers | SANOFI (FR) | 1995-08-22 | — | — | US | disclosed |
| EP-0636941-A1 | Deep ultraviolet absorbent and its use in pattern formation | WAKO PURE CHEMICAL INDUSTRIES LTD (JP) | 1995-02-01 | — | — | EP | disclosed |
| US-5258132-A | Stability, alkali resistance; liquid automatic dishwasher detergent | LEVER BROTHERS COMPANY, DIVISION OF CONOPCO, INC. (US) | 1993-11-02 | — | — | US | disclosed |
| US-5230822-A | Cleaning | LEVER BROTHERS COMPANY, DIVISION OF CONOPCO, INC. (US) | 1993-07-27 | — | — | US | disclosed |
| US-5200236-A | Spraying molten wax in a fluidized bed | LEVER BROTHERS COMPANY, DIVISION OF CONOPCO, INC. (US) | 1993-04-06 | — | — | US | disclosed |
| US-4829079-A | AMNESIA | ROUSSEL UCLAF (FR) | 1989-05-09 | — | — | US | disclosed |
| US-4087369-A | SURFACTANTS, BUILDERS, STORAGE STABILITY | THE PROCTER & GAMBLE COMPANY (US) | 1978-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152255-A1 | Organic Compounds | PPARG, FABP2, PPARA | CA12 4508/4885CA1 4431/4885CA2 3311/4885 |
| US-20070004704-A1 | Such as 6-Methyl-2-[4-(5-methyl-2-phenyl-oxazol-4-ylmethoxy)-benzenesulfonylamino]-benzoic acid which binds Peroxisome Proliferator-Activated Receptors; conditions in which impaired glucose tolerance, hyperglycemia and insulin resistance are implicated, such as type-1 and type-2 diabetes, and Syndrome X | PPARG, GPR119, PPARA | CA12 4831/4885CA1 4653/4885CA2 3811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.